Circio announces outcome of TG01/gemcitabine combination EU patent proceeding
· The EPO board of appeal moved to revoke the TG01/gemcitabine combination method of use patent in pancreatic cancer · The TG01 / gemcitabine combination was discontinued in 2019; the decision has no impact on ongoing clinical studies and other IP protections for TG01 Oslo, Norway, 24 November 2023 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA and immunotherapy medicines, today announces that the European Patent Office (EPO) board of appeal has moved to revoke the EU Patent 3140320 “Peptide vaccine comprising mutant RAS peptide and